Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Inclusion Criteria: * Fasting lipoprotein(a) (Lp(a)) 50 mg/dL or more at screening 1 * Fasting Low-density lipoprotein-cholesterol (LDL-C) 100 mg/dL or more at screening 1 * Lipid lowering therapy including statin dose unchanged for at least 8 weeks prior to screening * Target-to-background ratio (TBR) maximum higher than 1.6 (either right, left carotid or thoracic aorta) on fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT). Exclusion Criteria: * Currently receiving, or less than 4 weeks since receiving, treatment in another investigational device or drug study(ies), or participating in other investigational procedures * Known diagnosis of diabetes mellitus or screening fasting serum glucose ≥ 126 mg/dL or hemoglobin A1C (HbA1C) ≥ 6.5% * Subject with a history of homozygous familial hypercholesterolemia * History of a Cardiovascular event * Subject currently undergoing lipid apheresis * Known contraindications or limitations to FDG-PET/ CT (scanner weight limit, devices that can cause image artifacts, or carotid/aortic stents/grafts * Subject has had exposure to investigational drugs targeting Lp(a) within the last 12 months, prior to Screening * Other Exclusion Criteria May Apply.